Related Experiment Video
Updated: Feb 18, 2026
09:57
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
3.7K
Pediatric Psychogenic Nonepileptic Seizures: A Concise Review
Julia L Doss1, Sigita Plioplys2
1Department of Psychology, Minnesota Epilepsy Group, 225 Smith Avenue North, Suite 201, St Paul, MN 55102, USA.
Child and Adolescent Psychiatric Clinics of North America
|November 22, 2017
Summary
Psychogenic nonepileptic seizures (PNES) are a complex disorder impacting children's lives and healthcare. Early diagnosis and treatment are crucial for better outcomes and remission in pediatric PNES.
Area of Science:
- Pediatric neurology
- Child psychology
- Psychosomatic medicine
Background:
- Psychogenic nonepileptic seizures (PNES) present a complex biopsychosocial challenge in children.
- This condition significantly affects children's social, emotional, academic functioning, and family life.
- High healthcare service utilization is associated with PNES in pediatric populations.
Purpose of the Study:
- To highlight the impact of misdiagnosis and diagnostic delays in pediatric PNES.
- To emphasize the importance of timely and accurate diagnosis for improving prognosis.
- To underscore the benefits of prompt treatment initiation for remission.
Main Methods:
- Review of current understanding of PNES in children.
- Analysis of factors contributing to diagnostic challenges.
- Synthesis of evidence regarding treatment timing and outcomes.
Main Results:
- Diagnostic delays and misdiagnosis are common due to limited access to diagnostic standards and provider expertise.
- These delays negatively impact the prognosis of pediatric PNES.
- Treatment initiated closer to symptom onset is associated with better remission rates.
Conclusions:
- Addressing diagnostic barriers is essential for improving pediatric PNES outcomes.
- Timely intervention is critical for achieving remission in children with PNES.
- Integrated care approaches are needed to manage this complex disorder.
Related Concept Videos
01:13Seizures: Classification
1.7K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.7K
01:24Epilepsy and Seizures: Overview
1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
01:30Electroconvulsive Therapy
1.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
732
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
732
01:14Antiepileptic Drugs: Glutamate Antagonists
1.0K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.0K